

TERCICA INC  
Form 8-K  
August 31, 2007

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): 08/31/2007**

**Tercica, Inc.**

(Exact name of registrant as specified in its charter)

**Commission File Number: 000-50461**

**Delaware**  
(State or other jurisdiction of  
incorporation)

**26-0042539**  
(IRS Employer  
Identification No.)

**2000 Sierra Point Parkway**  
Suite 400  
Brisbane, CA 94005  
(Address of principal executive offices, including zip code)

**(650) 624-4900**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## Edgar Filing: TERCICA INC - Form 8-K

Information to be included in the report

### Item 8.01. Other Events

On August 30, 2007, Tercica, Inc. (the "Company") issued a press release announcing that its partner Ipsen had received notice of approval from the U.S. Food and Drug Administration (FDA) for marketing Somatuline Depot (lanreotide) injection for the treatment of acromegaly in the United States.

---

#### Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tercica, Inc.

Date: August 31, 2007

By: /s/ Stephen N. Rosenfield

---

Stephen N. Rosenfield  
Executive Vice President of Legal Affairs

**Exhibit Index**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
EX-99.	Press Release entitled "Somatuline Depot Receives FDA Marketing Approval for the Treatment of Acromegaly", dated August 30, 2007